This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(8)
- Annex to CHMP highlights(1)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(66)
- Direct healthcare professional communication(5)
- EPAR - All authorised presentations(12)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(46)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Full risk management plan(0)
- EPAR - Overview(13)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(11)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(13)
- EPAR - Public assessment report(14)
- EPAR - Risk-management-plan summary(14)
- EPAR - Scientific conclusion(8)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(1)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(3)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(2)
- Medicines under additional monitoring(0)
- Minutes(4)
- Newsletter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(43)
- Overview of comments(1)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(20)
- Position statement(0)
- PRAC recommendation on signal(11)
- Presentation(41)
- Press Release(36)
- Procurement(0)
- Public Statement(5)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(14)
- Regulatory and procedural guideline(3)
- Report(6)
- Scientific guideline(4)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(10)
- Summary of opinion - Initial authorisation(15)
- Supply shortage(0)
- Template or form(1)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(1)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(599)
- Compassionate use(17)
- Compliance and inspections(600)
- Corporate(115)
- (-)COVID-19(899)
- Data on medicines(987)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2185)
- Governance(707)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(47014)
- Medicines for use outside the EU(148)
- Medicine shortages(300)
- Mpox(39)
- Paediatrics(12241)
- Parallel distribution(15)
- Pharmacovigilance(9661)
- Procurement(132)
- Product information(6316)
- Quality of medicines(224)
- Rare diseases(8242)
- Referrals(3388)
- Regulatory and procedural guidance(3520)
- Research and development(495)
- Scientific advice(290)
- Scientific guidelines(1753)
- SME(259)
- Vaccines(1501)
- Veterinary limited markets(64)
Search results (899)
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Medicine overview
English (EN) (314.66 KB - PDF)
български (BG) (440.14 KB - PDF)
español (ES) (325.94 KB - PDF)
čeština (CS) (407.92 KB - PDF)
dansk (DA) (313.75 KB - PDF)
Deutsch (DE) (341.04 KB - PDF)
eesti keel (ET) (285.3 KB - PDF)
ελληνικά (EL) (445.33 KB - PDF)
français (FR) (334.3 KB - PDF)
hrvatski (HR) (372.28 KB - PDF)
italiano (IT) (319.96 KB - PDF)
latviešu valoda (LV) (392.79 KB - PDF)
lietuvių kalba (LT) (386.12 KB - PDF)
magyar (HU) (361.87 KB - PDF)
Malti (MT) (415.3 KB - PDF)
Nederlands (NL) (333.96 KB - PDF)
polski (PL) (394.94 KB - PDF)
português (PT) (322.48 KB - PDF)
română (RO) (397.61 KB - PDF)
slovenčina (SK) (405.97 KB - PDF)
slovenščina (SL) (396.69 KB - PDF)
Suomi (FI) (315.53 KB - PDF)
svenska (SV) (311.37 KB - PDF)
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - All authorised presentation
English (EN) (57.61 KB - PDF)
български (BG) (67.56 KB - PDF)
español (ES) (62.29 KB - PDF)
čeština (CS) (59.8 KB - PDF)
dansk (DA) (66.17 KB - PDF)
Deutsch (DE) (59.72 KB - PDF)
eesti keel (ET) (56.96 KB - PDF)
ελληνικά (EL) (82.04 KB - PDF)
français (FR) (58.29 KB - PDF)
hrvatski (HR) (69.55 KB - PDF)
íslenska (IS) (61.74 KB - PDF)
italiano (IT) (60.42 KB - PDF)
latviešu valoda (LV) (59.7 KB - PDF)
lietuvių kalba (LT) (74.75 KB - PDF)
magyar (HU) (64.46 KB - PDF)
Malti (MT) (72.83 KB - PDF)
Nederlands (NL) (57.23 KB - PDF)
norsk (NO) (58.52 KB - PDF)
polski (PL) (64.17 KB - PDF)
português (PT) (65.3 KB - PDF)
română (RO) (60.7 KB - PDF)
slovenčina (SK) (59.79 KB - PDF)
slovenščina (SL) (57.49 KB - PDF)
Suomi (FI) (57 KB - PDF)
svenska (SV) (58.72 KB - PDF)
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (1.13 MB - PDF)
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.
COVID-19 vaccines - Safety update: 8 December 2022
English (EN) (231.07 KB - PDF)
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Product information
English (EN) (709.52 KB - PDF)
български (BG) (831.75 KB - PDF)
español (ES) (1.36 MB - PDF)
čeština (CS) (781.7 KB - PDF)
dansk (DA) (738.48 KB - PDF)
Deutsch (DE) (826.38 KB - PDF)
eesti keel (ET) (714.13 KB - PDF)
ελληνικά (EL) (933.6 KB - PDF)
français (FR) (841.85 KB - PDF)
hrvatski (HR) (767.67 KB - PDF)
íslenska (IS) (735.22 KB - PDF)
italiano (IT) (849.88 KB - PDF)
latviešu valoda (LV) (731.52 KB - PDF)
lietuvių kalba (LT) (675.84 KB - PDF)
magyar (HU) (805.83 KB - PDF)
Malti (MT) (891.16 KB - PDF)
Nederlands (NL) (787.89 KB - PDF)
norsk (NO) (779.45 KB - PDF)
polski (PL) (779.29 KB - PDF)
português (PT) (820.98 KB - PDF)
română (RO) (799.55 KB - PDF)
slovenčina (SK) (760.59 KB - PDF)
slovenščina (SL) (723.08 KB - PDF)
Suomi (FI) (734.28 KB - PDF)
svenska (SV) (732.61 KB - PDF)
COVID-19 vaccines - Safety update: 10 November 2022
English (EN) (244.31 KB - PDF)
The European Medicines Agency (EMA) continues to monitor the safety of vaccines against COVID-19 and to ensure that they offer protection in the European Union (EU), even though the public health emergency has ended. On this page you can find answers to key questions on the effectiveness and safety of COVID-19 vaccines in general, as well as on...
COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 8 September 2021
English (EN) (492.14 KB - PDF)